FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140412964> ?p ?o ?g. }

• W2140412964 endingPage "399" @default.
• W2140412964 startingPage "392" @default.
• W2140412964 abstract "Object No definitive treatment for spinal cord injuries (SCIs) exists, and more research is required. The use of agmatine [4-(aminobutyl)-guanidine-NH 2 -CH 2 -CH 2 -CH 2 -CH 2 -NH-C(-NH 2 )(=NH)], a guanidinium compound formed by decarboxylation of l -arginine by arginine decarboxylase, is a neurotransmitter–neuromodulator with both N -methyl- d -aspartate receptor (NMDAR)–antagonizing and nitric oxide synthase (NOS)–inhibiting activities. The purpose of this study was to demonstrate the dose-dependent activity of agmatine, an inducible NOS (iNOS) inhibitor and selective NMDAR antagonist, on biochemical and functional recovery in an experimental rat SCI model. Methods This study involved 40 Wistar albino male rats. The rats were subjected to sleep–awake cycles for 7 days before surgery. In each group, general anesthesia was induced by a 60-mg/kg ketamine injection. For the surgical SCI model, a Yas¸argil aneurysm clip was placed in the spinal cord. The study was conducted in the following four main groups: Group I (control group) laminectomy only; Group II, trauma-only group and SCI; Group III, laminectomy, SCI and agmatine 50 mg/kg for 10 days; and Group IV, laminectomy, SCI, and agmatine 100 mg/kg for 10 days. On Day 1, no statistical difference was observed in any group (p < 0.005, analysis of variance [ANOVA] and the Fisher protected least significant difference [PLSD]). On Day 2, no statistical difference was noted among Groups II, III, and IV (p = 0.27, p = 0.42, and p = 0.76, respectively; ANOVA and Fisher PLSD). Beginning on Day 3, recovery in Groups III and IV differed significantly from that in Group II (p < 0.005, ANOVA and Fisher PLSD), and a statistically significant difference between Groups III and IV was observed, which also was present on Days 5, 7, and 10 (p = 0.003, p = 0.0024, and p = 0.0036, respectively; ANOVA and Fisher PLSD). Several observations were noteworthy: motor function scores were reduced significantly in the spinal cord–injured rats compared with the controls (p < 0.005); on Day 1, the agreement of motor function scores in rats in each SCI group indicated that the traumatic event had been replicated equally across all groups (p = 0.59, p = 0.59, and p = 0.28); a statistically significant difference in motor function scores developed on Day 3 between the rats subjected to trauma alone (Group II) and those treated with agmatine (Groups III and IV) (p < 0.005); and no statistically significant intergroup difference in motor function existed at any postinjury interval between the 50- and 100-mg/kg/day agmatine–treated rats (p > 0.005). Conclusions Agmatine administration following SCI was shown to reduce NO levels significantly. No statistically significant intergroup difference in the reduction of NO levels was found between rats treated with 50- and 100-mg/kg/day doses of agmatine. Administration of a 100-mg/kg/day dose of agmatine reduced the NO levels to those measured in controls. The authors conclude that with additional studies into the role of agmatine, this drug may be helpful in the treatment of patients with SCIs." @default.
• W2140412964 created "2016-06-24" @default.
• W2140412964 creator A5027245336 @default.
• W2140412964 creator A5027802206 @default.
• W2140412964 creator A5033628516 @default.
• W2140412964 creator A5046537178 @default.
• W2140412964 creator A5052805451 @default.
• W2140412964 creator A5070234704 @default.
• W2140412964 date "2006-05-01" @default.
• W2140412964 modified "2023-10-16" @default.
• W2140412964 title "Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo–control trial" @default.
• W2140412964 cites W1492707093 @default.
• W2140412964 cites W1498614006 @default.
• W2140412964 cites W1513989058 @default.
• W2140412964 cites W1590457525 @default.
• W2140412964 cites W1964947242 @default.
• W2140412964 cites W1965258293 @default.
• W2140412964 cites W1967987067 @default.
• W2140412964 cites W1969389571 @default.
• W2140412964 cites W1975629709 @default.
• W2140412964 cites W1981556150 @default.
• W2140412964 cites W1982525105 @default.
• W2140412964 cites W1984040467 @default.
• W2140412964 cites W1986689844 @default.
• W2140412964 cites W1989831685 @default.
• W2140412964 cites W1990669417 @default.
• W2140412964 cites W1990802251 @default.
• W2140412964 cites W2006617411 @default.
• W2140412964 cites W2014804210 @default.
• W2140412964 cites W2020449402 @default.
• W2140412964 cites W2022328640 @default.
• W2140412964 cites W2034117088 @default.
• W2140412964 cites W2035292299 @default.
• W2140412964 cites W2039311197 @default.
• W2140412964 cites W2041286410 @default.
• W2140412964 cites W2045972996 @default.
• W2140412964 cites W2048853229 @default.
• W2140412964 cites W2049005778 @default.
• W2140412964 cites W2050138229 @default.
• W2140412964 cites W2055959402 @default.
• W2140412964 cites W2071577536 @default.
• W2140412964 cites W2076770055 @default.
• W2140412964 cites W2077393263 @default.
• W2140412964 cites W2078264415 @default.
• W2140412964 cites W2082961737 @default.
• W2140412964 cites W2083419778 @default.
• W2140412964 cites W2083895027 @default.
• W2140412964 cites W2084861237 @default.
• W2140412964 cites W2085864993 @default.
• W2140412964 cites W2088003671 @default.
• W2140412964 cites W2107088892 @default.
• W2140412964 cites W2111392427 @default.
• W2140412964 cites W2114092892 @default.
• W2140412964 cites W2126994317 @default.
• W2140412964 cites W2138637179 @default.
• W2140412964 cites W2150403676 @default.
• W2140412964 cites W2158452174 @default.
• W2140412964 cites W2164595237 @default.
• W2140412964 cites W2166130920 @default.
• W2140412964 cites W2223031716 @default.
• W2140412964 cites W2444475331 @default.
• W2140412964 cites W4232841521 @default.
• W2140412964 cites W4249936317 @default.
• W2140412964 cites W4295401772 @default.
• W2140412964 doi "https://doi.org/10.3171/spi.2006.4.5.392" @default.
• W2140412964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16703907" @default.
• W2140412964 hasPublicationYear "2006" @default.
• W2140412964 type Work @default.
• W2140412964 sameAs 2140412964 @default.
• W2140412964 citedByCount "30" @default.
• W2140412964 countsByYear W21404129642012 @default.
• W2140412964 countsByYear W21404129642013 @default.
• W2140412964 countsByYear W21404129642014 @default.
• W2140412964 countsByYear W21404129642016 @default.
• W2140412964 countsByYear W21404129642017 @default.
• W2140412964 countsByYear W21404129642019 @default.
• W2140412964 countsByYear W21404129642020 @default.
• W2140412964 countsByYear W21404129642021 @default.
• W2140412964 countsByYear W21404129642022 @default.
• W2140412964 countsByYear W21404129642023 @default.
• W2140412964 crossrefType "journal-article" @default.
• W2140412964 hasAuthorship W2140412964A5027245336 @default.
• W2140412964 hasAuthorship W2140412964A5027802206 @default.
• W2140412964 hasAuthorship W2140412964A5033628516 @default.
• W2140412964 hasAuthorship W2140412964A5046537178 @default.
• W2140412964 hasAuthorship W2140412964A5052805451 @default.
• W2140412964 hasAuthorship W2140412964A5070234704 @default.
• W2140412964 hasConcept C118552586 @default.
• W2140412964 hasConcept C126322002 @default.
• W2140412964 hasConcept C134018914 @default.
• W2140412964 hasConcept C170493617 @default.
• W2140412964 hasConcept C185592680 @default.
• W2140412964 hasConcept C25498285 @default.
• W2140412964 hasConcept C2777468819 @default.
• W2140412964 hasConcept C2777622882 @default.
• W2140412964 hasConcept C2778334475 @default.
• W2140412964 hasConcept C2780091945 @default.
• W2140412964 hasConcept C2780775167 @default.

• next